Clinical Trial Update: BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing sorafenib with interferon alpha-2a in patients with unresectable or metastatic renal cell carcinoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interferon alfa-2a (interferon alfa-2a)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2010-12-15